Get Involved by Exploring Our Past Initiatives.

Here are a few reasons why blue is chosen and what it represents:

Global Unity: The color blue is often associated with harmony, trust, and unity. By lighting up prominent structures in blue, it symbolizes a global coming together to support and raise awareness for Parkinson's disease. It conveys a message of solidarity among individuals, organizations, and communities worldwide in the fight against Parkinson's.

Hope and Optimism: Blue is also a color that represents hope and optimism. For those living with Parkinson's disease, as well as their families and caregivers, the act of illuminating landmarks in blue signifies a beacon of hope for better treatments, increased understanding, and ultimately a cure for Parkinson's.

Visibility and Awareness: Blue is a striking color that attracts attention. By bathing iconic buildings and landmarks in blue light, it draws public awareness to Parkinson's disease and helps spark conversations about the challenges faced by those living with the condition. This visibility is crucial in educating the public and reducing stigma around Parkinson's.

Recognition and Respect: When significant landmarks are bathed in blue light for Parkinson's awareness, it sends a powerful message of recognition and respect to the Parkinson's community. It acknowledges the strength and resilience of individuals living with Parkinson's, as well as the efforts of researchers, healthcare professionals, and advocates working tirelessly to improve quality of life and find a cure.

In essence, lighting up buildings and landmarks in blue for Parkinson's awareness is a symbolic gesture that speaks volumes. It signifies unity, hope, visibility, and recognition, all of which are crucial in advancing awareness and support for Parkinson's disease.

Join us as we navigate the shadows, shedding light on the silent struggles that unfold in the darkness, offering a glimpse into the intricate tapestry of Parkinson's nighttime symptoms.

At AbbVie, our commitment to preserving personhood of people around the world living with Parkinson’s disease is unwavering. With more than three decades of experience in neuroscience, we are providing meaningful treatment options today and advancing innovation for the future. AbbVie's Neuroscience portfolio consists of approved therapies in neurological and psychiatric disorders, including migraine, Parkinson's disease, post-stroke spasticity, schizophrenia and others, along with a robust pipeline. Every challenge makes us more determined and drives us to discover and deliver advancements for those impacted by these conditions, their care partners, and clinicians.

For more information about AbbVie’s commitment to Neuroscience, click here.

Sleep is essential for health and well-being, yet a recent survey by PD Avengers and AbbVie found that 96% of People with Parkinson’s (PWPs) experience disrupted sleep, averaging 2.75 disruptions per night.

Key findings include:
🔹 PWPs face nearly six different sleep-related symptoms each night.
🔹 The most common issues are frequent awakenings (53%), insomnia (50%), and bradykinesia (41%).
🔹 65% struggle to turn over in bed, increasing to 84% for those with advanced PD.
🔹 Men experience more nocturia and REM Sleep Behavior Disorder, while women report higher rates of insomnia and joint stiffness.

Learn more about the survey results here:https://www.pdavengers.com/sleepsurvey

Parkinson’s is #1. Parkinson’s is fastest growing neurological disorder in the world. (CLICK FOR MORE FACTS ABOUT PARKINSON’S DISEASE)